Bellevue Group AG trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,430,500 shares of the company’s stock after selling 153,050 shares during the period. Neurocrine […]
Sectoral Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,445 shares of the company’s stock after buying an additional 410 shares during the period. Sectoral Asset Management […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]
Claret Asset Management Corp bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,565 shares of the company’s stock, valued at approximately $206,000. Other hedge funds and other […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by equities research analysts at UBS Group from $174.00 to $193.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 43.37% from the company’s […]